Beyond The Numbers: 5 Analysts Discuss Abbott Laboratories Stock
Portfolio Pulse from Benzinga Insights
Analysts have mixed views on Abbott Laboratories (NYSE:ABT), with recent ratings ranging from bullish to indifferent. Over the last three months, there have been 5 ratings with 4 somewhat bullish and 1 indifferent. The average 12-month price target is $115.6, down 3.18% from the previous $119.40. Analysts from Raymond James and Wells Fargo have raised their price targets, while Morgan Stanley lowered theirs. Abbott's market cap is above industry average, but it saw a revenue decline of -2.56% as of September 30, 2023. The company has a high net margin of 14.16% but a lower than average ROE of 3.85%. Its debt-to-equity ratio is conservative at 0.41.
January 03, 2024 | 6:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Abbott Laboratories has received mixed analyst ratings, with a downward adjustment in the average price target to $115.6. The company's financials show a revenue decline but strong profitability and conservative debt management.
The mixed analyst ratings and slight decrease in the average price target suggest a neutral short-term impact on ABT's stock price. The company's strong net margin and low debt-to-equity ratio are positive, but the revenue decline and lower ROE may raise concerns among investors. The overall impact is balanced, with no strong directional price movement expected in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100